JPRN-UMIN000029975Completed未知
Effect of SGLT2 inhibitor (Lusefi) on diabetic nephropathy Stratified analysis based on different original renal function category - CHAT-Lu
Fukuoka University Chikushi Hospital0 sites53 target enrollmentStarted: January 4, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 53
Study Overview
Brief Summary
There was no significant decrease in eGFR over 2 years, demonstrating renoprotective effects of luseogliflozin in patients with type 2 diabetes. Changes in eGFR were not correlated with changes in HbA1c. On the other hand, luseogliflozin had lesser renal protective effect in patients with overt proteinuria. In this study, blood sugar lowering effect, blood pressure lowering effect, liver function improving effect, and weight loss effect were also observed.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •past use of SGLT2 inhibitor severe ketoacidosis,diabetes coma,type1diabetes severe infection,pre and post operation,severe in injury pregnancy,lactation,potential pregnancy
Investigators
Similar Trials
Completed
Not Applicable
ong-term renoprotective effect of SGLT2 inhibitorstype 2 diabetes melllitusJPRN-UMIN000034387ephrology Division, JA Toride Medical Center60
Completed
Phase 3
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0IRCT20220708055414N1Orchidpharmed30
Completed
Not Applicable
A prospective observational study in type 2 diabetic patients showing reduced eGFR without albuminuriaJPRN-UMIN000038835Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease675
Completed
Not Applicable
The Effect of SGLT2 inhibitors on blood glucose variability in patients with type 1 diabetestype 1 diabetes mellitusJPRN-UMIN000039361Hokkaido University Hospital30
Recruiting
Not Applicable
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60